- Home
- NEE vs GILD Comparison
NEE vs GILD Comparison
Compare NEE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEE | GILD |
|---|---|---|
| Founded | 1925 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.1B | 187.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NEE | GILD |
|---|---|---|
| Price | $92.13 | $146.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 18 |
| Target Price | $93.38 | ★ $143.50 |
| AVG Volume (30 Days) | ★ 8.8M | 6.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 2.74% | 2.28% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $14.41 | $4.68 |
| Revenue Next Year | $8.48 | $6.10 |
| P/E Ratio | $27.64 | ★ $21.23 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $61.72 | $95.30 |
| 52 Week High | $95.91 | $157.29 |
Technical Indicators
Market Signals| Indicator | NEE | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 50.89 |
| Support Level | $79.30 | $143.09 |
| Resistance Level | $95.91 | $157.29 |
| Average True Range (ATR) | 2.03 | 3.27 |
| MACD | -0.55 | -1.43 |
| Stochastic Oscillator | 33.09 | 24.02 |
Price Performance
Historical ComparisonAbout NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with nearly 40 GW of generation capacity, including natural gas, nuclear, wind, and solar.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).